Millendo Therapeutics (MLND) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research downgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

MLND has been the topic of several other reports. Jefferies Financial Group began coverage on Millendo Therapeutics in a research report on Wednesday, March 13th. They issued a buy rating and a $22.00 price objective on the stock. ValuEngine downgraded Millendo Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 2nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $23.25.

Shares of Millendo Therapeutics stock opened at $15.86 on Tuesday. Millendo Therapeutics has a 52 week low of $6.77 and a 52 week high of $17.34. The stock has a market capitalization of $222.74 million, a PE ratio of -0.90 and a beta of 3.30. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02.

Millendo Therapeutics (NASDAQ:MLND) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.08). Millendo Therapeutics had a negative net margin of 10,128.37% and a negative return on equity of 52.20%. On average, equities research analysts anticipate that Millendo Therapeutics will post -3.25 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Morgan Stanley increased its holdings in shares of Millendo Therapeutics by 749.4% in the first quarter. Morgan Stanley now owns 3,041 shares of the company’s stock worth $46,000 after purchasing an additional 2,683 shares during the last quarter. Prosight Management LP increased its holdings in shares of Millendo Therapeutics by 5.5% in the first quarter. Prosight Management LP now owns 270,762 shares of the company’s stock worth $4,061,000 after purchasing an additional 14,023 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Millendo Therapeutics by 16.5% in the first quarter. Renaissance Technologies LLC now owns 104,297 shares of the company’s stock worth $1,564,000 after purchasing an additional 14,790 shares during the last quarter. Citigroup Inc. increased its holdings in shares of Millendo Therapeutics by 6,052.5% in the first quarter. Citigroup Inc. now owns 6,091 shares of the company’s stock worth $91,000 after purchasing an additional 5,992 shares during the last quarter. Finally, Private Advisors LLC increased its holdings in shares of Millendo Therapeutics by 9.1% in the first quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock worth $229,000 after purchasing an additional 1,279 shares during the last quarter. Institutional investors and hedge funds own 42.70% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Further Reading: Diversification in Your Portfolio

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.